APRE Aprea Therapeutics Inc

Price (delayed)

$6.69

Market cap

$36.33M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.95

Enterprise value

$14.68M

Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor ...

Highlights
Aprea Therapeutics's revenue has increased by 2.5% from the previous quarter
The company's gross profit rose by 2.5% QoQ
APRE's EPS has dropped by 132% since the previous quarter but it has surged by 94% year-on-year
Aprea Therapeutics's net income has surged by 87% YoY but it has decreased by 8% QoQ
The quick ratio has contracted by 45% YoY and by 19% from the previous quarter
The equity has contracted by 34% YoY and by 16% from the previous quarter

Key stats

What are the main financial stats of APRE
Market
Shares outstanding
5.43M
Market cap
$36.33M
Enterprise value
$14.68M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.47
Price to sales (P/S)
41.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
25.17
Earnings
Revenue
$583,231
EBIT
-$15.51M
EBITDA
-$15.5M
Free cash flow
-$12.27M
Per share
EPS
-$3.95
Free cash flow per share
-$3.39
Book value per share
$4.54
Revenue per share
$0.16
TBVPS
$6.26
Balance sheet
Total assets
$22.65M
Total liabilities
$5.7M
Debt
$0
Equity
$16.95M
Working capital
$18.14M
Liquidity
Debt to equity
0
Current ratio
5.14
Quick ratio
4.94
Net debt/EBITDA
1.4
Margins
EBITDA margin
-2,658.3%
Gross margin
100%
Net margin
-2,449.6%
Operating margin
-2,652.8%
Efficiency
Return on assets
-52.4%
Return on equity
-65.6%
Return on invested capital
N/A
Return on capital employed
-84.9%
Return on sales
-2,659.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

APRE stock price

How has the Aprea Therapeutics stock price performed over time
Intraday
10.21%
1 week
5.35%
1 month
-7.08%
1 year
45.12%
YTD
42.34%
QTD
42.34%

Financial performance

How have Aprea Therapeutics's revenue and profit performed over time
Revenue
$583,231
Gross profit
$583,231
Operating income
-$15.47M
Net income
-$14.29M
Gross margin
100%
Net margin
-2,449.6%
Aprea Therapeutics's net income has surged by 87% YoY but it has decreased by 8% QoQ
Aprea Therapeutics's operating income has soared by 86% YoY but it has decreased by 7% from the previous quarter
The net margin has declined by 4.9% since the previous quarter
The company's operating margin fell by 4.5% QoQ

Growth

What is Aprea Therapeutics's growth rate over time

Valuation

What is Aprea Therapeutics stock price valuation
P/E
N/A
P/B
1.47
P/S
41.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
25.17
APRE's EPS has dropped by 132% since the previous quarter but it has surged by 94% year-on-year
APRE's P/B is 110% above its last 4 quarters average of 0.7 but 43% below its 5-year quarterly average of 2.6
The equity has contracted by 34% YoY and by 16% from the previous quarter
Aprea Therapeutics's revenue has increased by 2.5% from the previous quarter

Efficiency

How efficient is Aprea Therapeutics business performance
The company's return on equity has surged by 91% YoY but it fell by 18% QoQ
Aprea Therapeutics's ROA has soared by 82% YoY but it has decreased by 15% from the previous quarter
APRE's return on sales is down by 4.8% since the previous quarter

Dividends

What is APRE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for APRE.

Financial health

How did Aprea Therapeutics financials performed over time
The quick ratio has contracted by 45% YoY and by 19% from the previous quarter
The current ratio has decreased by 45% YoY and by 16% from the previous quarter
The debt is 100% smaller than the equity
The equity has contracted by 34% YoY and by 16% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.